Inlyta (Axitinib)

Axitinib selectively blocks the tyrosine kinase activity of vascular endothelial growth factor receptors VEGFR‑1, VEGFR‑2 and VEGFR‑3. By inhibiting these receptors, it reduces signaling that promotes new blood‑vessel growth (angiogenesis) within tumors, thereby limiting nutrient supply and tumor progression.

The specific dose of Inlyta is determined by the prescribing physician based on individual patient factors, including prior treatments, renal function, and tolerability. The prescriber will select the appropriate tablet strength and dosing schedule in accordance with approved labeling and clinical guidelines.

Safety data for axitinib in pregnancy and lactation are limited, and the drug may pose risks to the fetus or nursing infant. It is generally contraindicated in pregnant or breastfeeding women unless the potential benefit justifies the risk, and effective contraception is recommended during treatment.

To request Inlyta, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will verify trade or institutional credentials before providing pricing, availability, shipping details (including any required temperature control) and import documentation.

Inlyta belongs to the class of VEGFR tyrosine‑kinase inhibitors, similar to drugs such as sunitinib and pazopanib. Compared with some alternatives, axitinib is often used after progression on first‑line therapy and may offer a different side‑effect profile, particularly a higher incidence of hypertension but lower rates of certain cytopenias. Choice of therapy depends on prior treatment history and patient tolerance.

Inlyta tablets should be stored at ambient temperature, below 25 °C, in their original container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Inlyta is taken orally, usually once daily, with or without food, as directed by the treating physician. Patients should swallow the tablet whole with a glass of water and follow any specific instructions regarding timing relative to other medications or meals. Consistent daily intake helps maintain steady drug levels.

The most serious risks of Inlyta include severe hypertension, arterial thromboembolic events such as heart attack or stroke, gastrointestinal perforation, and rare but potentially fatal hemorrhage. Patients should be monitored closely for signs of these events, and any sudden severe symptoms should prompt immediate medical attention.

Inlyta is contraindicated in patients with known hypersensitivity to axitinib or any tablet excipients. It should be used with caution, or avoided, in individuals with uncontrolled hypertension, recent major cardiovascular events, active bleeding disorders, or severe hepatic impairment. Pregnant or breastfeeding women should also avoid the medication unless the benefits outweigh the risks.